Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation.
Recent studies indicate that thrombopoietin (TPO) may be highly effective in mobilizing autologous peripheral blood stem cells (PBSCs) for transplantation in patients undergoing intensive chemotherapy. The yield of CD34+ progenitor cells can be increased as can the percentage of patients achieving adequate grafts for use in transplantation. However, the effect of TPO in patients with hematologic malignancies undergoing induction or postremission chemotherapy or in the stem-cell transplantation setting has not been demonstrated. Further study is warranted for better definition of the role of TPO in the treatment of severe thrombocytopenia in these settings.
Linker
C
C
Division of Hematology/Oncology, University of California, San Francisco 94143-0324, USA.
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy; D013926:Thrombopoietin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; D011092:Polyethylene Glycols; D013926:Thrombopoietin